GB0813142D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
GB0813142D0
GB0813142D0 GBGB0813142.7A GB0813142A GB0813142D0 GB 0813142 D0 GB0813142 D0 GB 0813142D0 GB 0813142 A GB0813142 A GB 0813142A GB 0813142 D0 GB0813142 D0 GB 0813142D0
Authority
GB
United Kingdom
Prior art keywords
novel compounds
novel
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0813142.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GBGB0813142.7A priority Critical patent/GB0813142D0/en
Publication of GB0813142D0 publication Critical patent/GB0813142D0/en
Priority to ARP090102692A priority patent/AR072809A1/es
Priority to ES09780586T priority patent/ES2396960T3/es
Priority to JP2011517910A priority patent/JP5688850B2/ja
Priority to US12/503,125 priority patent/US8288388B2/en
Priority to CA2730471A priority patent/CA2730471C/en
Priority to KR1020117001109A priority patent/KR101599087B1/ko
Priority to TW098123842A priority patent/TW201016677A/zh
Priority to US13/054,265 priority patent/US8530478B2/en
Priority to PL09780587T priority patent/PL2300432T3/pl
Priority to JP2011517911A priority patent/JP5543966B2/ja
Priority to ES09780587T priority patent/ES2396962T3/es
Priority to MX2011000600A priority patent/MX2011000600A/es
Priority to AU2009272762A priority patent/AU2009272762B2/en
Priority to CN200980127788XA priority patent/CN102099337B/zh
Priority to PCT/EP2009/059012 priority patent/WO2010007073A1/en
Priority to EP09780587A priority patent/EP2300432B1/en
Priority to UY0001031990A priority patent/UY31990A/es
Priority to EA201170209A priority patent/EA018621B1/ru
Priority to EP09780586A priority patent/EP2346828B1/en
Priority to BRPI0916622-0A priority patent/BRPI0916622A2/pt
Priority to PCT/EP2009/059011 priority patent/WO2010007072A1/en
Priority to IL210446A priority patent/IL210446A/en
Priority to ZA2011/00014A priority patent/ZA201100014B/en
Priority to US13/568,211 priority patent/US8536183B2/en
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
GBGB0813142.7A 2008-07-17 2008-07-17 Novel compounds Ceased GB0813142D0 (en)

Priority Applications (25)

Application Number Priority Date Filing Date Title
GBGB0813142.7A GB0813142D0 (en) 2008-07-17 2008-07-17 Novel compounds
PCT/EP2009/059011 WO2010007072A1 (en) 2008-07-17 2009-07-15 Piperazine derivatives used as cav2.2 calcium channel modulators
MX2011000600A MX2011000600A (es) 2008-07-17 2009-07-15 Derivados de piperazina usados como moduladores del canal de calcio cav2.2.
CN200980127788XA CN102099337B (zh) 2008-07-17 2009-07-15 用作cav2.2钙通道调节剂的哌嗪衍生物
JP2011517910A JP5688850B2 (ja) 2008-07-17 2009-07-15 Cav2.2カルシウムチャネルモジュレーターとして使用されるピペラジン誘導体
US12/503,125 US8288388B2 (en) 2008-07-17 2009-07-15 3-pyridylcarbonyl-piperazinylsulfonyl derivatives
CA2730471A CA2730471C (en) 2008-07-17 2009-07-15 Piperazine derivatives used as cav2.2 calcium channel modulators
KR1020117001109A KR101599087B1 (ko) 2008-07-17 2009-07-15 Cav2.2 칼슘 채널 모듈레이터로서 사용되는 피페라진 유도체
TW098123842A TW201016677A (en) 2008-07-17 2009-07-15 Novel derivatives
US13/054,265 US8530478B2 (en) 2008-07-17 2009-07-15 Piperazine derivatives used as CAV2.2 calcium channel modulators
PL09780587T PL2300432T3 (pl) 2008-07-17 2009-07-15 Pochodne piperazyny stosowane jako modulatory kanałów wapniowych CAV2.2
JP2011517911A JP5543966B2 (ja) 2008-07-17 2009-07-15 Cav2.2カルシウムチャネルモジュレーターとして使用されるピペラジン誘導体
ES09780587T ES2396962T3 (es) 2008-07-17 2009-07-15 Derivados de piperazina utilizados como moduladores de los canales de calcio Cav2.2
ARP090102692A AR072809A1 (es) 2008-07-17 2009-07-15 Compuesto de (3- piridinilcarbonil)-4-(fenilsulfonilpiperazina ), su uso para la elaboracion de unmedicamento para el tratamiento del dolor y composicion farmaceutica que lo comprende
AU2009272762A AU2009272762B2 (en) 2008-07-17 2009-07-15 Piperazine derivatives used as Cav2.2 calcium channel modulators
ES09780586T ES2396960T3 (es) 2008-07-17 2009-07-15 Derivados de piperazina utilizados como moduladores de los canales de calcio Cav2.2
PCT/EP2009/059012 WO2010007073A1 (en) 2008-07-17 2009-07-15 Piperazine derivatives used as cav2.2 calcium channel modulators
EP09780587A EP2300432B1 (en) 2008-07-17 2009-07-15 Piperazine derivatives used as cav2.2 calcium channel modulators
UY0001031990A UY31990A (es) 2008-07-17 2009-07-15 Nuevos derivados
EA201170209A EA018621B1 (ru) 2008-07-17 2009-07-15 ПРОИЗВОДНЫЕ ПИПЕРАЗИНА, ПРИМЕНЯЕМЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ КАЛЬЦИЕВОГО КАНАЛА Ca2.2
EP09780586A EP2346828B1 (en) 2008-07-17 2009-07-15 Piperazine derivatives used as cav2.2 calcium channel modulators
BRPI0916622-0A BRPI0916622A2 (pt) 2008-07-17 2009-07-15 derivados de piperazina usados como moduladores de canal de cálcio cav2,2
ZA2011/00014A ZA201100014B (en) 2008-07-17 2011-01-03 Piperazine derivatives used as cav2.2 calcium channel modulators
IL210446A IL210446A (en) 2008-07-17 2011-01-03 History of fibrin and medicinal preparations containing them
US13/568,211 US8536183B2 (en) 2008-07-17 2012-08-07 3-pyridylcarbonyl-piperazinylsulfonyl derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0813142.7A GB0813142D0 (en) 2008-07-17 2008-07-17 Novel compounds

Publications (1)

Publication Number Publication Date
GB0813142D0 true GB0813142D0 (en) 2008-08-27

Family

ID=39737239

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0813142.7A Ceased GB0813142D0 (en) 2008-07-17 2008-07-17 Novel compounds

Country Status (19)

Country Link
US (3) US8530478B2 (enExample)
EP (2) EP2300432B1 (enExample)
JP (2) JP5688850B2 (enExample)
KR (1) KR101599087B1 (enExample)
CN (1) CN102099337B (enExample)
AR (1) AR072809A1 (enExample)
AU (1) AU2009272762B2 (enExample)
BR (1) BRPI0916622A2 (enExample)
CA (1) CA2730471C (enExample)
EA (1) EA018621B1 (enExample)
ES (2) ES2396962T3 (enExample)
GB (1) GB0813142D0 (enExample)
IL (1) IL210446A (enExample)
MX (1) MX2011000600A (enExample)
PL (1) PL2300432T3 (enExample)
TW (1) TW201016677A (enExample)
UY (1) UY31990A (enExample)
WO (2) WO2010007072A1 (enExample)
ZA (1) ZA201100014B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0813142D0 (en) * 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB201000685D0 (en) 2010-01-15 2010-03-03 Glaxo Group Ltd Novel compounds
EP2665729B1 (en) * 2011-01-19 2015-04-01 Convergence Pharmaceuticals Limited Piperazine derivatives as cav2.2 calcium channel blockers
CN103781759B (zh) 2011-06-27 2016-01-13 纽朗制药有限公司 氟化的芳基烷基氨基甲酰胺衍生物
EP3495360A1 (en) * 2014-04-14 2019-06-12 Grünenthal GmbH Heteroaryl substituted heterocyclyl sulfones
US9896440B2 (en) 2014-04-14 2018-02-20 Grünenthal GmbH Aryl substituted heterocyclyl sulfones
GB201516183D0 (en) * 2015-09-14 2015-10-28 Calchan Ltd Novel pharmaceutical composition
TW201718557A (zh) 2015-10-08 2017-06-01 歌林達有限公司 經吡唑基取代之四氫吡喃基碸
TW201726128A (zh) 2015-10-08 2017-08-01 歌林達有限公司 經吡唑基取代之四氫哌喃基碸
MX2019012818A (es) * 2017-04-26 2020-07-14 Cavion Inc Metodos para mejorar la memoria y la cognicion y para el tratamiento de trastornos de la memoria y cognitivos.
CN118085389B (zh) * 2024-03-11 2024-11-05 伟建实业(苏州)有限公司 一种环保型抗菌海绵及其制备方法

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988006371A1 (fr) 1987-02-13 1988-08-25 Mitsubishi Denki Kabushiki Kaisha Demarreur/chargeur pour moteurs
US5112824A (en) 1989-12-08 1992-05-12 Merck & Co., Inc. Benzofuran compounds as class III antiarrhythmic agents
US5498711A (en) 1993-02-03 1996-03-12 Thiokol Corporation Synthesis of 4,10-dinitro-2,6,8,12-tetraoxa-4,10-diazatetracyclo[5.5.0.05,903,11]dodecane
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
EP0809636B1 (en) 1995-02-13 2002-09-04 G.D. Searle & Co. Substituted isoxazoles for the treatment of inflammation
IL117580A0 (en) 1995-03-29 1996-07-23 Merck & Co Inc Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them
IL117805A0 (en) 1995-04-07 1996-08-04 Schering Corp Carbonyl piperazinyl and piperidinyl compounds
UA57002C2 (uk) 1995-10-13 2003-06-16 Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування
FR2744450A1 (fr) 1996-02-02 1997-08-08 Pf Medicament Nouvelles naphtylpiperazines derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
EP1288206B1 (en) 1996-04-12 2008-09-17 G.D. Searle LLC Substituted benzenesulfonamide derivatives as prodrugs of COX-2 inhibitors
US5880128A (en) 1996-05-08 1999-03-09 Schering Corporation Carbonyl piperazinyl and piperidinyl compounds
SI0912518T1 (en) 1996-07-18 2003-12-31 Merck Frosst Canada & Co. Substituted pyridines as selective cyclooxygenase-2 inhibitors
WO1998017625A1 (en) 1996-10-22 1998-04-30 Daiichi Pharmaceutical Co., Ltd. Novel remedies for infectious diseases
GB9623283D0 (en) 1996-11-08 1997-01-08 Zeneca Ltd Heterocyclic derivatives
UA56197C2 (uk) 1996-11-08 2003-05-15 Зенека Лімітед Гетероциклічні похідні
EP0986551B1 (en) 1997-05-30 2006-08-02 Takeda Pharmaceutical Company Limited Sulfonamide derivatives, their production and use
GB9715894D0 (en) 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic derivatives
CO4960662A1 (es) 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
EP1369421B1 (en) 1997-09-05 2004-11-03 Glaxo Group Limited Pharmaceutical compositions comprising 2,3-Diaryl-pyrazolo[1,5-B]pyridazine derivatives
UA59433C2 (uk) 1998-01-27 2003-09-15 Авентіс Фармасьютікалс Продактс Інк. ЗАМІЩЕНІ ОКСОАЗАГЕТЕРОЦИКЛІЧНІ ІНГІБІТОРИ ФАКТОРА Хa ТА ПРОМІЖНІ СПОЛУКИ ДЛЯ ЇХ ОТРИМАННЯ
IL141724A0 (en) 1998-08-28 2002-03-10 Scios Inc INHIBITORS OF P38-α KINASE
WO2000026216A1 (en) 1998-11-03 2000-05-11 Glaxo Group Limited Pyrazolopyridine derivatives as selective cox-2 inhibitors
CA2320730A1 (en) 1998-12-23 2000-07-06 Renhua Li Thrombin or factor xa inhibitors
AUPP818099A0 (en) 1999-01-14 1999-02-11 Fujisawa Pharmaceutical Co., Ltd. New n-containing heterocyclic compounds
AU2661400A (en) 1999-02-27 2000-09-21 Glaxo Group Limited Pyrazolopyridines
GB9927844D0 (en) 1999-11-26 2000-01-26 Glaxo Group Ltd Chemical compounds
GB0003224D0 (en) 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
AU2001241927A1 (en) 2000-02-28 2001-09-12 Scios Inc. Inhibitors of p38-alpha kinase
WO2001066534A2 (en) 2000-03-09 2001-09-13 Abbott Laboratories Cyclic and bicyclic diamino histamine-3 receptor antagonists
WO2001076693A1 (en) 2000-04-10 2001-10-18 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
FR2812198B1 (fr) 2000-07-28 2008-07-18 Sod Conseils Rech Applic DERIVES D'AMIDINES INHIBITEURS DE PHOSPHATASES cdc25
GB0021494D0 (en) 2000-09-01 2000-10-18 Glaxo Group Ltd Chemical comkpounds
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
US7223751B2 (en) 2001-04-26 2007-05-29 Kolon Ind. Inc. Sulfonamide derivatives, intermediate thereof, its preparation methods, and pharmaceutical composition comprising the same
DE10155684A1 (de) 2001-11-13 2003-05-22 Bayer Ag Thiazolharnstoffe
EP1314733A1 (en) 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
FR2833261B1 (fr) 2001-12-06 2004-07-02 Yang Ji Chemical Company Ltd Nouveaux composes inhibiteurs specifiques de la phospholipase a2 secretee non pancreatique humaine du groupe ii
KR100464261B1 (ko) 2002-01-24 2005-01-03 주식회사 파나진 Pna 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법
OA12792A (en) 2002-03-13 2006-07-10 Janssen Pharmaceutica Nv Sulfonyl-derivatives as novel inhibitors of histone deacetylase.
DE10217006A1 (de) 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
AU2003223627B2 (en) 2002-04-18 2006-10-12 Schering Corporation (1-4-piperidinyl) benzimidazole derivatives useful as histamine H3 antagonists
CN1181065C (zh) 2002-05-08 2004-12-22 上海医药工业研究院 芳烷甲酰烷基哌嗪衍生物及其作为脑神经保护剂的应用
DE10319435B4 (de) * 2003-04-25 2018-07-26 Whitecryption Corporation Verfahren zur Verarbeitung von Daten zum Schutz eines Softwareprogramms vor Rekonstruktion
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
WO2005089502A2 (en) 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
SE0400850D0 (sv) 2004-03-30 2004-03-31 Astrazeneca Ab Novel Compounds
WO2005113542A2 (en) 2004-05-20 2005-12-01 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
DE102004035672A1 (de) 2004-07-22 2006-03-30 Windmöller & Hölscher Kg Verkürzte Stapelbildung
JP5149009B2 (ja) 2004-09-20 2013-02-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヒトステアロイル−CoAデサチュラーゼを阻害するためのピリダジン誘導体
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
DE102004054053A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Bradykinin-B1-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102005013967A1 (de) 2004-11-05 2006-10-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Bradykinin-B1-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7759339B2 (en) 2005-03-31 2010-07-20 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
JP2009519349A (ja) 2005-12-15 2009-05-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Cb2受容体を変調する化合物
KR20080080201A (ko) 2005-12-21 2008-09-02 쉐링 코포레이션 히스타민 h3 길항제로서 유용한 치환된 아닐린 유도체
CA2633379A1 (en) 2005-12-22 2007-07-05 Merck & Co., Inc. Substituted piperidines as calcium channel blockers
US7625880B2 (en) 2006-01-13 2009-12-01 Pharmacyclics, Inc. Inhibitors of tyrosine kinases and uses thereof
US20070259879A1 (en) 2006-03-06 2007-11-08 Trimeris, Inc. Piperazine and piperidine biaryl derivatives
EP2004619A1 (en) * 2006-03-23 2008-12-24 Amgen Inc. 1-phenylsulfonyl-diaza heterocyclic amide compounds and their uses as modulators of hydroxsteroid dehydrogenases
US8247442B2 (en) 2006-03-29 2012-08-21 Purdue Pharma L.P. Benzenesulfonamide compounds and their use
WO2007118854A1 (en) 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and the use thereof
US8791264B2 (en) 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
JP5539717B2 (ja) 2006-07-14 2014-07-02 塩野義製薬株式会社 オキシム化合物およびその使用
WO2008024284A2 (en) * 2006-08-21 2008-02-28 Merck & Co., Inc. Sulfonylated piperazines as cannabinoid-1 receptor modulators
EP2065369A4 (en) 2006-08-23 2011-12-28 Astellas Pharma Inc UREA CONNECTION OR SALT THEREOF
US7928103B2 (en) 2006-10-17 2011-04-19 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
BRPI0720732A2 (pt) 2006-12-18 2014-04-08 7Tm Pharma As Moduladores de receptor cb1
US7507736B2 (en) 2007-02-07 2009-03-24 Hoffmann-La Roche Inc. Indol-2-yl-piperazin-1-yl-methanone derivatives
US7648979B2 (en) 2007-02-07 2010-01-19 Hoffmann-La Roche Inc. 5-amido-(1H-indol-2-yl)-piperazin-1-yl-methanone derivatives
US8399486B2 (en) 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
WO2008150447A1 (en) 2007-05-31 2008-12-11 Euro-Celtique S.A. Amide compounds and the use thereof
WO2008150470A1 (en) 2007-05-31 2008-12-11 Shionogi & Co., Ltd. Oxyimino compounds and the use thereof
WO2009040659A2 (en) 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
WO2009045382A1 (en) 2007-10-04 2009-04-09 Merck & Co., Inc. Substituted aryl sulfone derivatives as calcium channel blockers
GB0813142D0 (en) * 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
EA018621B1 (ru) 2013-09-30
TW201016677A (en) 2010-05-01
US8530478B2 (en) 2013-09-10
KR101599087B1 (ko) 2016-03-02
US8288388B2 (en) 2012-10-16
EP2346828A1 (en) 2011-07-27
CA2730471C (en) 2016-12-06
IL210446A (en) 2014-01-30
EP2346828B1 (en) 2012-10-03
ES2396962T3 (es) 2013-03-01
BRPI0916622A2 (pt) 2019-04-09
US20120302746A1 (en) 2012-11-29
AU2009272762B2 (en) 2013-08-15
US20100022555A1 (en) 2010-01-28
JP5543966B2 (ja) 2014-07-09
CN102099337A (zh) 2011-06-15
WO2010007073A1 (en) 2010-01-21
CN102099337B (zh) 2013-08-21
EP2300432A1 (en) 2011-03-30
MX2011000600A (es) 2011-05-24
JP5688850B2 (ja) 2015-03-25
IL210446A0 (en) 2011-03-31
US8536183B2 (en) 2013-09-17
UY31990A (es) 2010-01-05
AR072809A1 (es) 2010-09-22
US20110130379A1 (en) 2011-06-02
CA2730471A1 (en) 2010-01-21
WO2010007072A1 (en) 2010-01-21
EP2300432B1 (en) 2012-10-03
JP2011528020A (ja) 2011-11-10
JP2011528019A (ja) 2011-11-10
EA201170209A1 (ru) 2011-08-30
PL2300432T3 (pl) 2013-03-29
ZA201100014B (en) 2011-09-28
ES2396960T3 (es) 2013-03-01
AU2009272762A1 (en) 2010-01-21
KR20110031199A (ko) 2011-03-24

Similar Documents

Publication Publication Date Title
GB0823467D0 (en) Novel Compounds
GB0806536D0 (en) Novel compounds
GB0813142D0 (en) Novel compounds
GB0808747D0 (en) Novel compounds
GB0811587D0 (en) Novel Compounds
IL212799A0 (en) Novel compounds
GB0812849D0 (en) Novel compounds
GB0804592D0 (en) Novel compounds
GB0807103D0 (en) Compounds
GB0810981D0 (en) Novel compounds
GB0810228D0 (en) Novel compounds
IL213032A0 (en) Novel compounds
GB0813144D0 (en) Novel compounds
GB0808030D0 (en) Novel compounds
GB0804326D0 (en) Novel compounds
GB0800411D0 (en) Novel compounds
GB0809479D0 (en) Novel compounds
GB0803212D0 (en) Novel compounds
GB0813711D0 (en) Novel compounds
GB0804414D0 (en) Novel compounds
GB0806289D0 (en) Novel compounds
GB0806368D0 (en) Novel compounds
GB0804591D0 (en) Novel compounds
GB0807050D0 (en) Novel compounds
GB0810229D0 (en) Novel compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)